TALAPRO-3 in mCSPC: Prof. Agarwal discusses the trial results
In this episode, UROONCO PCa associate editor Prof. Claudia Kesch interviews Dr. Neeraj Agarwal, from Dana-Farber Cancer Institute on the recent results of the TALAPRO-3 trial. This trial investigates the efficacy and safety of TALA + ENZA in men with mCSPC bearing HRR gene alterations.
Dr. Agarwal elaborates on the rationale of this trial and the key results. They also discuss the control arm in more detail, heterogeneity and HRR alteration, plus clinical practice of managing anaemia and treatment strategy in mHSPC.
To know more on this trial, read the abstract. For more updates on prostate cancer, please visit our educational platform UROONCO PCa.
For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.